Biomarker testing

Biomarkers are becoming increasingly important in many cancers, for screening, diagnosis, prognosis, and prediction of response to particular therapies.

In non-small cell lung cancer (NSCLC), therapies that target certain biomarkers are revolutionising treatments for patients, heralding a new era of personalised medicine. On Boehringer Ingelheim’s “Let’s Test Now” pages, you can learn more.